Julie Lachal

Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration

Kenji Namoto, Eric Vangrevelinghe, Rainer Machauer, Dirk Behnke et autres

Large Tumor Suppressor kinases LATS1 and 2 (LATS1/2) are serine/threonine kinases and core regulators of the Hippo-YAP pathway. Inhibition of LATS1/2 promotes nuclear translocation of nonphosphorylated YAP, thereby initiating a downstream cascade promoting cell proliferation. We set out to investigate the potential …

cn (code pays fourni par la source)

NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo

Kenji Namoto, Clara Baader, Vanessa Orsini, Alexandro Landshammer et autres

ch, de, us, mx, gb (code pays fourni par la source)

Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach

Edwige Lorthiois, James Roache, David Barnes‐Seeman, Eva Altmann et autres

Abstract The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we …

ch, cn, us (code pays fourni par la source)